Compare Cytokinetics Inc (CYTK) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Zoetis Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 3.5× Cytokinetics Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Zoetis Inc for 70 Days on average.
| CYTK | ZTS | |
|---|---|---|
Market Cap | $8.62B | $30.20B |
Volume | 2,594,626 | 6,175,327 |
Sector | Health | Health |
52-Week High | $87.26 | $147.53 |
52-Week Low | $54.76 | $69.09 |
Typical Hold Time | 19 Days | 70 Days |
Enterprise Value | $8.72B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong profitability with a 27.69% net income margin and 64.91% ROE, though recent quarterly earnings have been inconsistent. Analyst consensus is a $87.33 price target with no sell ratings. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and undervaluation.
ZTS presents a compelling value opportunity with a low P/E of 11.92 and robust margins, but faces risks from competitive pressures and volatile earnings. Upside potential exists if the company executes on international growth and maintains its industry-leading profitability, though investors should monitor Q3 2026 results for confirmation of recovery trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
